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Summary
Lipopolysaccharide (LPS) potently stimulates humanimmunodeficiency virus type 1-long terminal
repeat (HIV1-LTR) CAT constructs transfected into monoryte/macrophage-like cell lines but
not a T cell line. This effect appears to be mediated through the induction of nuclear factor
KB (NF-KB). Electrophoretic mobility shiftassays demonstrate that LPS induces a DNA binding
activity indistinguishable from NF-KB in U937 and THP-1 cells.
LPS is also shown to dramatically increase HIV-1 production from a chronically infected
monoryte/macrophage-like cloned cell line, U1, which produces very low levels ofHIV-1 at baseline.
The stimulation of viral production from this cell line occurs only if these cells are treated with
granulocyte/macrophage colony-stimulating factor (GM-CSF) before treatment with LPS. This
stimulation of HIV-1 production is correlated with an increase in the level of HIV-1 RNA and
an activation of NF-KB. LPS is not able to induce HIV-1 production in a cloned T cell line.
The effect of LPS on HIV-1 replication occurs at picogram per milliliter concentrations and may
be clinically significant in understanding the variability of the natural history of HIV-1 infection.
C
ontrol of the replication of HIV-1 involves both virus-
encoded encoded proteins and cellular factors activated by a va-
riety of exogenous stimuli (1-3). The role of cellular events
is evident because stimulation of the HIV-1 promoter within
the long terminal repeat (LTR)' is produced by various cel-
lularstimuli including phorbol esters, TNF-a, and heterolo-
gous viralproteins (3). Many of these agents appear to func-
tion through the activationofnuclear factor KB (NF-KB) which
binds to two 11 by motifs in the HIV-1 LTR and consequently
activates LTR-driven RNA transcription (3-7). The effects
of certain cellular stimuli on HIV-1 replication have been
studied in transient transfection assays of the HIV1-LTR
linked to reporter genes and by utilizing chronically infected
cell lines and primary cells (3-14).
HIV-1 growth in infected people is difficult to study directly
and so must be modeled by examining influences on cells
in culture. Factors that stimulate HIV-1 replication in cell
culture may also regulate HIV-1 expression in CD4 lympho-
cytes and monocytes/macrophages in vivo (1-3). These are
1 Abbrndations used in this paper. CAT, chloramphenicol acetyl
transferase; GM-CSF, granulocyte/macrophage colony-stimulating
factor; LTR, long terminal repeat; NF-KB, nuclear factor KB.
the two major cell types known to harbor HIV-1 (1). In the
periphery, CD4 lymphocytes carry most of the virus (15),
but the monoryte/macrophage may be the major cell type
infected in the central nervous system and other tissues (1,
16, 17). The monoryte/macrophage may act as a "Trojan
Horse," concealing the virus from the immune system, and
it may be among the first cells infected by HIV-1 in patients
(1, 17).
Many agents that stimulate HIV-1 replication do so in both
T cells and monoryte/macrophages (6-8). With the excep-
tion of granulocyte/macrophage colony stimulating factor
(GM-CSF), agents that induce HIV-1 replication only in
monoryte/macrophages are not well described (9, 12, 14).
Stimuli that selectively affect HIV-1 replication in mono-
cyte/macrophages might, therefore, hold significant clinical
importance.
The monoryte/macrophage can be studied either directly
after culturing or through cell line models. Primary mono-
cyte/macrophages have thus far been refractory to transfec-
tion with significant efficiency, and therefore, are not suit-
able for the studyofgene expression and regulation. We have
thus chosen to study the U937 and THP-1 monoryte/mac-
rophage-like cell lines as model systems.
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constituent ofthecell wall of gram-negativebacteria, stimu-
latesgene expression directed from theHIV1-LTRin mono-
cyte/macrophage-like cell lines but not in T cell lines. LPS
has this effect at physiologically significant concentrations and
appears to do so through the activation of NF-KB, which
in turn binds to two KB enhancer elements in the U3 region
of the HIV1-LTR (4).
Contrary to a previous report (7), we find no correlation
between the state of differentiation of the available mono-
cyte/macrophage-like cell lines and the level of constitutive
expression o£ activated NF-KB. However, we do find that ac-
tivation ofNF-KBby LPSandconsequent stimulation of HIV-1
from a cloned monocyte/macrophage-like cell line (9) occur
only after treatment with GM-CSF. This suggests that the
developmental maturity of HIV-1-infected monocyte popu-
lations may determine whether they respond to LPS with
an increase in HIV-1 production.
Materials and Methods
Cells.
￿
A monoblastoid cell line, U937,was maintained in RPMI
1640 mediasupplemented with 10% FCS, penicillin (250 U/ml), and
streptomycin (250 14g/ml) (18). The cell line THP-I, derived from
monocytic leukemic cells, wasmaintained as above (19). Ahuman
Tcell lineJurkat was also maintained as previously described(20).
A subclone of HIV-1-infected U937 cells, U1, was donated by
Thomas Folksandwasobtainedfrom theAIDS Research andRef-
erence Program, MAID, National Institutes of Health, Bethesda,
MD.This cell line shows aminimalamount ofconstitutive expres-
sion of HIV-1 (9).
A variant of the CEM T-cell line, A3.01, was infected with the
LAV strain of HIV-1 and a subdone, ACH-2, was obtained that
exhibits minimalamountsofconstitutive expression ofHIV-1 (10).
This cell line wasdonatedby Thomas Folks and wasobtained from
the AIDS Research and Reference Program, NIAID, NIH.
Plasmids.
￿
The plasmid HIV-CAT, containing the HIV=1-LTR
upstream ofthechloramphenicol acetyl transferase (CAT) gene has
been described (4). Theplasmid, HIVNF-KBA CAT, with muta-
tions in the NF-KB sites, rendering these sites unable to bind the
NH-KB protein, has also previously been described (4).
A plasmid 018) containing two KB sites from the K enhancer
whichwere cloned into Hind III and SalIsitesupstream ofatrun-
cated mouse c-fos promoter linked to the CAT gene, was kindly
provided by J. Pierce (21). The cfos promoter was truncated to
nucleotide 56 toremove phorbol ester and serum-responsive ele-
ments. A plasmid lacking KB sites butretaining the truncatedcfos
promoter was also obtained from J. Pierce, Whitehead Institute,
Cambridge, MA (21).
Transfections and CATAssays.
￿
Allcell lines were transfected using
DEAE-dextran. In brief, cells were washed twice with PBS and
resuspended in serum-free suspension Tris-buffered saline (22). 10'
cells were then treated with DEAE-Dextran at 200 ug/ml (Phar-
macia, Uppsala, Sweden) containing 10 Wg of plasmid in 1 ml.
Cells were treated 90 min at 37°Cwith frequent mixing. A 10%
DMSO shockwasperformed andthecellswere washed twicewith
PBS and then resuspended to a concentration of 5 x 105 cells/ml
in RPMI 1640 media with 10% FCS.
24 h after transfection, thecellswere exposedto either LPSEsch-
erichia coli 0127:B8 (Difco Laboratories,Detroit, MI), recombinant
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humanTNF-a(Genzyme Corp., Cambridge, MA), or PMA(Sigma
Chemical Co., St. Louis, MO) and PHA (Sigma). Some transfec-
tions received no treatments. A rabbit anti-human TNF-a neu-
tralizing antibody (1 pl neutralizes 10' U of TNF-a) was also
addedto some transfections (Genzyme Corp.). 44 haftertransfec-
tion, cellextracts were prepared for CATassayandprotein concen-
trations were determined by the method of Bradford (23) (Bio-
RadLaboratories, Richmond, CA). The quantity of protein used
per assay was normalized (70 jug for U937 and THR1 cells and
100 ttg forJurkat cells). CATassays were performed according to
themethod of Gorman et al. (24).Percentconversion of acetylated
products by liquid scintillation was calculated.
Transfections were performed between two and six times and
results are reported as the arithmetic mean + SEM.
CellularExtracts and Electrophoretic MobilityShift Assays(EMSA).
Cellular extracts were prepared from 5 x 10'cellswith or without
treatment forvarious time periods with GM-CSF (Genetics Insti-
tute, Cambridge, MA), LPS, or PMA plus PHA according to a
protocol, with some modifications, describedby Baeuerle andBal-
timore (25). Cells were washed twice with ice-cold PBS and then
resuspended in lysis buffer that consisted of 20 mM Hepes (pH
7.9), 0.35 M NaCl, 20% glycerol, 1% NP-40, 1 MM MgC12,
1 mM DTT, 0.5 mMEDTA,0.1 mM EGTA,1 mM PMSF,0.3 jug/
ml antipain (Sigma), and0.3 I~g/ml leupeptin (Sigma). Afterlysis
on ice for 10 min, particulate material wasremovedby centrifuga-
tion at 11,000gfor15 minat 4°C. Thesupernatant's protein con-
tent wasmeasured by an assayusingbicinchoninic acid according
to themanufacturer's instructions (PierceChemical Co., Rockford,
IL). Electrophoretic mobility shiftanalyses to detect NF-rcB binding
were carried out as previously described (26).
The 32P-labeled DNA probe was a44-bp HindIII-Sall fragment
cut from aplasmid 010), containing a single «B enhancer site up-
stream of the mouse cfos promoter (21). This fragment was end-
labeled with (32P]CTP and [32P]ATP (New England Nuclear,
Boston, MA) using the Klenow fragment of E. coli DNA poly-
merase I (Boehringer-Mannheim Biochemicals, Indianapolis, IN).
Bandsother than free probeandNK-KB activity are noted with
cellular extracts made with this method. They representcytoplasmic
DNA binding proteins and/or proteolytic digestion products of
nuclear proteins (Feinberg, M., and D. Baltimore, manuscript in
preparation).
The competition experiments were performedwith various nano-
gram amountsof an unlabeleddouble-stranded oligonucleotidecon-
taining both HIV-1 NP-0-binding motifs and an oligonucleotide
with mutations in the HIV-1 NF-KB-binding motifs, previously
shownto notbind NF-KB(4)(kindly providedby Dr.M.Lenardo).
HIV-1 KB oligonucleotide: 5'TCGACAAGGGACTTT000CTG-
GGGACTTTCCAGGGC3'. Mutant HIV-1 KB oligortudeotide:
5'TCGACAACTCACTTTCCGCTGCTCACTTTCCAGGC3'.
Stimulation ofHIVI Expressionfrom U1 andACH-2 CellLines.
￿
5
x 105 were seeded in 2 ml of medium in 24-wellplates (Costar,
Cambridge, MA). They were either left untreated or a variety of
agents were addedincluding TNF-ac, LPS, and PMA plus PHA.
After 24 h, samples of supernatants were removed daily for 3 d.
Thep24antigenlevelwasmeasured usingasensitive ELISAmethod
(Dupont, Wilmington, DE) following themanufacturer's instruc-
tions. Some cultures were pretreated with GM-CSF for 24 h be-
fore other agents were added. AntiTNF-a neutralizing antibody
(Genzyme Corp.) was added where indicated.
Each experiment was repeated at least twice usingduplicate or
triplicate samples perexperiment. Datapresentedrepresentthearith-
metic mean ± SEM.Results
Activation ofHIV1-LTR by LPS in Monocyte/Macrophage-
like Cell Lines. To examine the effect of LPS on HIV1-
LTR-directed gene expression, various cell lines were trans-
fected with an HIV1-LTRCAT construct . LPS (10 hg/ml)
greatly increased the amount ofCAT activity produced from
this HIV1-LTR CAT construct after transient transfection
of both U937, and the phenotypically more mature THP-1
cell lines (Fig . 1, A and B) . PMA plus PHA (50 ng/ml and
2 wg/ml) and TNF-a (1,000 U/ml) also stimulated CAT
production in both cell lines, but to lesser degrees than LPS
(Fig. 1, A and B) . Our ability to demonstrate HIV1-LTR
CAT stimulation byPMA andPHA in THP-1 cells is at vari-
ance with a previous report (7) . A concentration of TNF-ci
of 1,000 U/ml, as illustrated in Fig. 1, resulted in the greatest
level of stimulation in a dose-response curve with this cytokine.
Above this level cytotoxicity was evident (data not shown) .
Mock transfections consistently gave percent conversion levels
of <1% .
To determine whether LPS could induce CAT activity in
T cells, Jurkat cells were transfected with the HIV1-LTR
CAT plasmid . CAT activity was not stimulated by LPS (10
wg/ml) in Jurkat cells, although PMA and PHA, as previ-
ously demonstrated (4), stimulated CAT activity in this cell
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line (Fig . 1 C) . TNF-ot was also demonstrated to stimulate
the HIV1-LTR-directed CAT gene in Jurkat cells (data not
shown) .
To determine whether LPS might stimulate HIV1-LTR
CAT at physiologically significant concentrations, various
amounts of LPS were added to transient transfections . LPS
was able to stimulate HIV1-LTR CAT in U937 cells to a
significant degree at concentrations as low as 10 pg/ml . This
effect was not evident at 1 pg/ml (Fig. 2) . Stimulation de-
creased over the range of LPS concentrations from 100 ng
to 10 pg/ml.
To examine whether the KB sites in the HIV1-LTR were
necessary for LPS-induced CAT stimulation, anHIV1-LTR
CAT construct with mutant NF-KB binding sites (4) (HIV-
NF-KB A CAT) was transfected into U937 andTHP-1 cells .
LPS (10 hg/ml), when added 24 h after transfection, led to
no significant stimulation inCAT activity in U937 orTHR1
cells (Fig . 1, A and B) . CAT activity from this construct
was also not stimulated above baseline by TNF-ca or PMA
and PHA treatment in the U937 and THP-1 cell lines (data
not shown) .
To examine whether regions other than the KB sites in the
HIV1-LTR were required for LPS-induced CAT stimulation,
a plasmid U18) containingtwo KB sites from the is enhancer
Figure 1 .
￿
CAT stimulation in transient transfections of U937, THP-1, and Jurkat cells. (A) U937
cells, (B) THP-1 cells, (C) Jurkat cells . 107 cells were transfected with 10 ug of various plasmids and
treated with different agents at 24 h (PMA 50 ng/ml and PHA 2 kg/ml, TNF-a 1,000 U/ml, or LPS
10 P.g/ml) . Cell extracts were harvested for CAT assays 44 h after transfection (see Materials and
Methods) . The level of endotoxin in the medium and the FCS was 0 .3 and 1.4 endotoxin units (EU)
per milliliter, respectively . The level of endotoxin in the TNF-a was <0.001 EU per unit of TNF-a .
The percent conversion of [
14C]chloramphenicol was measured and bar graphs illustrate the arithmetic
mean of between two and six separate experiments + SEM . The transfections not treated with any
agent are noted at the bottom of the graph by a negative sign . The "fold increase shown at the
bottom of HIVCAT transfections represent the increased conversion of
[t
4C]chloramphenicol compared
with the untreated HIV-CAT transfections which are given the value of 1 . HIV-CAT plasmid is a HIV1-
LTR linked to a CAT gene. The HIV NF-KB A CAT plasmid is an HIV1-LTR with mutations in both
KB sites linked to a CAT gene . Fos NF-KB CAT plasmid (J18) contains two KB sites upstream of a trun-
cated cfos promoter linked to the CAT gene.
Pomerantz et al .Figure 2 .
￿
Dose response of HIVCAT stimulation by LPS in U937
cells. 107 U937 cells were transfected with 10 jig of the HIV-CAT
plasmid . 24 h after transfection, various amounts of LPS were added
to give differing final concentrations of LPS in the medium. Cell ly-
sates were harvested 44 h after transfection . Percent conversions of
[t4C]chloramphenicol are the arithmetic means + SEM of three inde-
pendent transfections .
upstream ofa truncated cfos promoter linked to a CAT gene
(21) was transfected intoU937 and THR1 cells . When treated
with LPS (10 Wg/ml), a large stimulation of CAT activity
in U937 and THP-1 cells was demonstrated (Fig. 1, A and
Figure 3 .
￿
AntiTNF-a antibody treatments of HIV-CAT transfec-
tions in U937 cells. U937 cells were transfected with 10 jig ofHIV
CAT plasmid and treated with LPS or TNFa, with or without anti-
TNFa antibody, 24 h after transfection . 20 Fl of antiTNF-a anti-
body, which neutralizes 2 x 10 4 U of TNF-a, were added to appro-
priate transfections . (Lane 1) No treatment, (lane 2) LPS (10 kg/ml),
(lane 3) LPS + antiTNF-a antibody, (lane 4) TNF-a (1,000 U/ml),
and (lane 5) TNF-ot + antiTNF-a antibody. The percent conver-
sions of [t4C]chloramphenicol are the arithmetic means t SEM of
three independent transfections . The autoradiograph shown is a repre-
sentative example of these experiments .
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B) . A plasmid lacking the KB sites but retaining the cfos pro-
moter linked to a CAT gene (21) was not stimulated byLPS
in either cell line (data not shown) .
Transfections of theHIV-NF-KBA CAT andJ18 plasmids
indicate that the LPS stimulation of the HIV1-LTR CAT
in the U937 and THP-1 cell lines is based on the induction
ofNF-KB and its binding toKB enhancer motifs in theLTR .
To ascertain ifthe LPS-induced CAT stimulation was caused
by TNF-ci released from cells, HIV1-LTR CAT constructs
were transfected intoU937 cells, which were then either treated
with LPS (10 pg/ml) plus or minus anti-TNF-ot antibody,
TNF-ci (1,000 U/ml) plus or minus antiTNF-a antibody,
or left untreated (Fig . 3) . AntiTNF-a antibody had no
significant effect on LPS-induced stimulation ofHIV1-LTR
CAT but reduced by r-86% the level of CAT activity in-
duced by TNF-ot (Fig. 3) . AntiTNF-ci antibody was also
unable to block LPS-induced CAT stimulation in the THP-1
cell line (data not shown) .
LPS Induces an Activity in Monocyte/Macrophage-like Cell
Lines that Binds toKB sites onEMSA . Cellular extracts were
prepared by a brief protocol (25), rather than the nuclear
extracts prepared by the method ofDignam et al . (27), for
EMSA . This method gave more background bands but al-
lowed the use of small amounts of cells and minimized
proteolysis common in the manipulation of monocyte/
macrophage-like cell lines . A binding activity, indistinguish-
able fromNF-KB, was found in extracts ofU937 and THP-1
cells treated with LPS but not Jurkat cells.
This binding activity was induced after only 30 min of
LPS treatment of U937 cells and increased over treatment
periods up to 2 h (Fig. 4, lanes 2-4) . Prolonged treatment
with LPS showed persistent but reduced levels of NF-KB-like
binding activity (Fig . 4, lane 5) .
NF-KB-like binding activity was also detected in THP-1
cells stimulated with LPS (Fig . 4, lane 12), but contrary to
a previous report (7), little of this activity was found in our
unstimulated THP-1 cells (Fig. 4, lane 11) . This LPS-inducible
complex comigrated with a PMA plus PHA-inducible com-
plex in U937, THP-1, andJurkat cells (Fig. 4, lanes 10, 17,
19) . Peak levels of NF-KB-like activity were induced by
PMA/PHA in U937 and THP-1 cells with overnight treat-
ment, while PMA/PHA treatment gave its greatest effect
in Jurkat cells after 2 h (data not shown) . LPS is a much
more potent stimulus for NF-«B-like binding activity inU937
and THP-1 cells than PMA plus PHA. LPS was unable to
stimulate NF-KB-like binding activity inJurkat cells (Fig. 4,
lane 20) .
The LPS-inducible complex was specifically competed away
by . an unlabeled fragment composed of both KB sites from
the HIV1-LTR in reactions with cellular extracts from both
U937 andTHP-1 cells (Fig. 4, lanes 6-8 and 13-15) . An un-
labeled fragment with mutations in the KB sites of theHIV1-
LTR was unable to compete with this binding activity from
LPS-stimulated U937 and THP-1 cells (Fig . 4, lanes 9 and
16) . The unlabeled competitor fragment effectively competed
with binding activity found inPMA plus PHAtreatedJurkat
cell extracts, while the mutant unlabeled fragment showedFigure 4 .
￿
Electrophoretic mobil-
ity shift assays of U937, THP-1,
and Jurkat cells . 5 x 107 cells in
50 ml of medium were treated
with various agents over differing
time periods. Cellular extracts
were prepared and EMSAs per-
formed as described in Materials
and Methods .
(Lane 1) U937, no treatment
(noted by negative [-] sign).
(Lanes 2-5) U937 + LPS (10 t~g/
ml) over various stimulation time
periods. (Lanes 6-8) U937 + LPS
and differing amounts of unlabeled
competitor (comp.) . (Lane 9) U937
+ LPS and 20 ng of mutant unla-
beled competitor. (Lane 10) U937
+ PMA (50 ng/ml) plus PHA (2
Fag/ml) overnight stimulation .
(Lane 11) THP-1, no treatment .
(Lane 12) THP1 + LPS, 2 h stim-
ulation. (Lane 13-15) THP-1 +
LPS and differing amounts of un-
labeled competitor. (Lane 16)
THP-1 + LPS and 20 ng of mu-
tant unlabeled competitor. (Lane
17) THP-1 + PMA and PHA
overnight stimulation . (Lane 18)
Jurkat, no treatment . (Lane 19)
Jurkat + PMA and PHA, 2 h
stimulation . (Lane 20) Jurkat +
LPS, 2 h stimulation . (Lane 21)
Jurkat + PMA and PHA 20 ng competitor. (Lane 22) Jurkat + PMA and PHA and 20 ng mutant competitor. The autoradiograph illustrated
was slightly overexposed to demonstrate changes in the NF-KB band in lanes where various amounts of unlabeled competitor were added . (Filled
arrowheads) NF-KB band; (open arrowheads) unbound probe.
no competition with this binding activity (Fig. 4, lanes 21
and 22) . The above data demonstrate that LPS induces a
binding activity indistinguishable from NF-KB in mono-
cyte/macrophage-like cell lines .
Stimulation ofHIVI Production byLPS in UI Cells Pretreated
with GM-CSF . TheU1 cell line is a subclone of HIV-1-in-
fected U937 cells which constitutively produce very low
amounts of virus . These cells can be stimulated to produce
much greater amounts of HIV-1 by treatment with TNF-a,
PMA, and GM-CSF (7, 9) .
We were able to reproduce these findings. We noted a 320-
and 27-fold increase in p24 antigen levels over baseline with
TNF-a and GM-CSF, respectively (Fig . 5, A and B) . PMA
plus PHA induced p24 antigen levels to >100 ng/ml by day
3 (data not shown) . LPS alone, however, failed to yield a con-
sistent increase in p24 antigen levels (Fig . 5 A) . There was
<0.2 ng/ml of p24 antigen in the supernatant of unstimu-
lated U1 cells by the third day in culture.
Reasoning that the U1 cell line might be a relatively im-
mature subclone ofU937 cells, we attempted to differentiate
this cell line usingGM-CSF before treatment with LPS. After
treatment for 24 h with GM-CSF, LPS led to a 200-fold in-
crease in p24 antigen levels in the supernatant compared with
untreated cultures, and a 7.4-fold increase compared with cul-
tures treated solely with GM-CSF by day 3 after LPS treat-
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ment (Fig . 5 B) . We were further able to demonstrate that
afterGM-CSF pretreatment, HIV-1 production could be fur-
ther augmented in the U1 cell line with concentrations of
LPS as low as 100 pg/ml (Fig. 6) . All ofthe stimulatory effects
on HIV-1 production in theU1 cell line resulted in increased
levels of HIV-1-specific RNA (Pomerantz, R .J ., D . Trono,
M . Feinberg, and D . Baltimore, manuscript submitted for
publication) .
To examine whether the LPS-mediated stimulation ofHIV-1
in U1 cells was due to the release ofTNF-a from the GM-
CSF-treated UI cells,we added antiTNF-a neutralizing an-
tibody to cultures treated with GM-CSF plus LPS . This an-
tibody had a minimal effect on the level of virus production
inGM-CSF pretreated cells to whichLPS was added, although
it was able to totally ablate the stimulation of virus produc-
tion induced by 1,000 U/ml of TNF-a (Fig. 5, A and B) .
A chronically HIV-1-infected T cell line, ACH-2, which
constitutively produces small amounts ofvirus, was also treated
with a variety of agents. Although TNF-a led to a significant
increase in viral production, LPS alone, GM-CSF alone, and
GM-CSF plusLPS had no effect on viral replication (Fig. 5C) .
Stimulation ofNF-KB-like Binding Activity in UI Cells byLPS
afterPretreatment withCM.CSF . To demonstrate that the LPS-
mediated increase in HIV-1 production in U1 cells pretreated
with GM-CSF was correlated with the activation of NF-KB,c
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￿
Production of HIV-1 from the U1 and ACH-2 cell lines.
(A and B) Ll1 cells, (C) ACH-2 cells. 5 x 105 cells were placed in
2 ml of medium in 24-well plates. Different agents were added and
p24 antigen levels in the supernatants were determined daily for 3 d.
The treatment regimens included LPS (10 ug/ml) with or without
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cellular extracts were made after a variety of treatment pro-
tocols and the binding reactions to a labeled probe with 2
KB sites were studied by EMSA.
LPS alone was unable to induce NF-«B-like activity in U1
cells (Fig. 7, lane 2). NF-KB-like activity was not stimulated
by LPS alone in U1 cells after 1, 2, 6, 24, and 36 h of treat-
ment (data not shown). As previously reported (7), a small
amount of NF-KB-like activity was induced in the U1 cell
line after 24 h of treatment with PMA and PHA (Fig. 7,
lane 4).
As reported for other cell lines (6), treatment of the U1
cell line for 48 h with GM-CSF did not induce NF-KB-like
activity (Fig. 7, lane 3). GM-CSF did not induce NF-KB-like
activity in U1 cells when treated for time periods ofbetween
2 and 36 h (data not shown). LPS, though, was able to in-
duce a small quantity ofNF-KB-like activity after the U1 cells
were pretreated for 24 h with GM-CSF (Fig. 7, lane 5). LPS
induced NF-KB-like activity in GM-CSF pretreated U1 cells
only if added to the medium for 24 h or longer (data not
shown).
This NF-«B-like activity comigrated with a band induced
by PMA plus PHA in Jurkat cells (Fig. 7, lane 9) and was
specifically competed away with an unlabeled DNA fragment
with two KB sites from the HIV1-LTR but not a fragment
with mutations in these KB sites (Fig. 7, lanes 6 and 7). This
DNA binding activity was, therefore, indistinguishable from
NF-KB. In multiple experiments, only relatively small quan-
tities of NF-KB were induced by PMA plus PHA or GM-
CSF plus LPS in the U1 cell line compared with levels in-
duced in uncloned and uninfected U937 cells.
To further demonstrate that NF-KB was activated by PMA
plus PHA and GM-CSF plus LPS in U1 cells, these cells were
transfected with the Fos NF-KB CAT (J18) plasmid. Treat-
ment of these treatment transfections with PMA plus PHA
or GM-CSF plus LPS led to a significant stimulation of CAT
activity. Treatment with GM-CSF alone or LPS alone did
not stimulate CAT activity (data not shown).
Discussion
We have demonstrated here that LPS potently activates the
HIV1-LTR in monocyte/macrophage-like cell linesbut not
in a T cell line. The LPS effect appears to be mediated through
NF-KB. LPS increased HIV-1 production from a cloned mono-
cyte/macrophage-like cell line which was pretreated with GM-
CSF. These LPS effects were demonstrated at picogram per
milliliter concentrations.
LPS, which is a major constituent ofthe cell walls of gram
negative bacteria, has a plethora ofeffects on a variety ofcells.
The release of TNF-ca from monocyte/macrophages by LPS
antiTNF-a antibody (4 Al), TNF-a (1,000 U/ml) with or without
antiTNF-a antibody, GM-CSF (500 U/ml) alone, and GM-CSF
(500 U/ml) for 24 h followed by LPS (10 ug/ml). Certain cultures
were left untreated. The level of endotoxin in the GM-CSF was
<0.001 EU per unit of GM-CSR Data points represent the arithmetic
means ± SEM of two to three separate experiments performed in
duplicate.Figure 6 .
￿
Dose response of HIV-1 production in GM-CSF
pretreated U1 cells by LPS. Various amounts of LPS were added to
U1 cells pretreated with GM-CSF (500 U/ml) for 24 h . p24 antigen
levels were measured from these supernatants on the third day after
LPS was added . Each bar is the arithmetic mean + SEM of two ex-
periments performed in duplicate .
leads to many but not all the pathophysiologic effects noted
during endotoxemia (28, 29) . LPS activates macrophages and
induces Interleukin I, Interleukin 6 and Interferon ti produc-
tion (29, 30) . LPS is also a murine B lymphocyte mitogen
and will activate protein kinase C and induce NF-KB in pre-
B cells although it has little effect on T lymphocytes (31) .
Many of these LPS-induced effects are seen with nanograrn
or picogram per milliliter concentrations (28, 29) . LPS may
not activate NF-KB in T cells for lack of an LPS receptor
or for other reasons.
SinceLPS induces production ofTNF-a (28) andTNF-a
was able to activate transcription of our HIV-1-CAT con-
struct, it could be that the effect ofLPS on HIV1-LTR-driven
transcription is indirect . An antibody toTNF-a did not block
the LPS-induced HIV1-LTR CAT stimulation . Moreover,
EMSAs demonstrated that LPS activation ofNF-KB begins
within 30 min or less of treatment . It is not likely, therefore,
that an LPS-induced increase in production or release ofTNF-a
is the major mechanism underlying this effect . The TNF-a
promoter itself has KB-like regions (32), and consequently,
both stimulation ofTNF-a and stimulation of HIV-1 may
be independent results of LPS-mediated NF-KB activation .
A recent report has demonstrated that LPS-treated primary
macrophages produce cytokines, including TNF-a, which
stimulate HIV-1 production in T lymphocytes (10) . This is
certainly a possible mechanism by which LPS stimulation of
some monocyte/macrophage populations might affect not only
HIV-1 production directly in monoryte/macrophages but also
have an indirect effect on HIV-1 replication in T lympho-
cytes in vivo .
It is instructive to note that a significant effect on HIV-1
production was not demonstrated when theU1 cell line was
treated with LPS alone . Only after pretreatment with GM-
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Figure 7 .
￿
EMSA of U1 cells . (Lane 1) U1 cells, no treatment .
(Lane 2) U1 cells treated with LPS (10 ug/ml) for 48 h . (Lane 3) U1
cells treated with GM-CSF (500 U/ml) for 48 h . (Lane 4) U1 cells
treated with PMA (50 ng/ml) and PHA (2 Ftg/ml) for 24 h . (Lane
5) U1 cells treated with GM-CSF for 24 h then LPS for 24 h . (Lanes
6 and 7) U1 cells pretreated with GM-CSF for 24 h and then LPS
for 24 h plus 20 ng of unlabeled competitor (comp) or mutant com-
petitor (mut. comp), respectively. (Lane 8) Jurkat, no treatment . (Lane
9) Jurkat plus PMA and PHA for 2 h . This representative autoradio-
graph was slightly overexposed to properly illustrate the small quan-
tity of NF-KB that was activated in U1 cells (uppermost band in
lanes 4, 5, and 7) . (Closed arrowheads) NF-KB band; (open arrowheads)
unbound probe.
CSF, which has been noted to induce differentiation and matu-
ration in monocytic precursor cells (33), was LPS able to stimu-
late high levels of HIV-1 production. It appears that the U1
cell subclone of HIV-1-infected U937 cells may be quite im-mature and either lack an LPS receptor or some component
of the proximal NF-KB activation pathway induced by LPS.
Only after maturation by GM-CSF can the U1 cell line re-
spond to LPS with an increase in HIV-1 production from
its integrated provirus. As with the HIV1-LTR CAT trans-
fections, the LPS-effect on viralproduction is largely a direct
one and is not mediated via a release of TNF-a. An anti-
TNF-a antibody was able to decrease only slightly the level
ofHIV-1 production in the U1 cell line pretreated with GM-
CSF to which LPS was added. Only if endogenously pro-
duced TNFci is more difficult to neutralize compared with
exogenous TNF-a might a portion of the LPS effect still be
mediated through TNF-oc.
A recent studyhas demonstrated that pretreating primary
macrophages with LPS may protect them from HIV-1 infec-
tion, possibly through activation (13). This study is not at
variance with our data. Treatment of macrophages with LPS
before infection with HIV-1 may have a different effect on
HIV-1 production than treatment ofchronically HIV-1-infected
monoryte/macrophages. That LPS may protect macrophages
from HIV-1 infection and increase HIV-1 production from
chronically infected monoryte/macrophages suggests that, in
vivo, the effects of LPS on HIV-1 may be complex.
The induction of NF-KB as the cellular mediator of the
LPS effect on HIV-1 production in monoryte/macrophage-
like cells is yet another system controlled by this transcrip-
tional regulator (for review see reference 34) . The induction
of NF-KB does not require protein synthesis, and probably
occurs through the release of an inhibitor (IKB), bound to
NF-KB (25). The free form of NF-KB may then migrate to
the nucleus where it binds to 10 or 11 by enhancer-motifs
present in a variety ofpromoters. These include HIV-1, CMV,
IFN-/3, IL2, and the human IgK enhancer, to name but a
few (34).
NF-KB activation takes place via more than one pathway
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